Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 8/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24036538 | 1.00 | BACE1 (0.36) | BACE1MRGPRX4FFAR4L3MBTL1FFAR1 | |
| SCHEMBL25753637 | 0.90 | EPHX2 (0.35) | MRGPRX4SMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL24036537 | 0.90 | EPHX2 (0.35) | MRGPRX4SMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL25753581 | 0.84 | CTSA (0.38) | MEN1KMT2APDE2AHPGD | |
| SCHEMBL24036721 | 0.84 | CTSA (0.38) | MEN1KMT2APDE2AHPGD | |
| SCHEMBL24036882 | 0.84 | FDFT1 (0.37) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL25753619 | 0.84 | FDFT1 (0.37) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL25752818 | 0.84 | CTSA (0.35) | SMN1; SMN2 | |
| SCHEMBL25623352 | 0.83 | GPR139 (0.40) | MRGPRX4GPR139PDE2A | |
| SCHEMBL24036886 | 0.83 | MEN1 (0.34) | BACE1L3MBTL1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | UBE CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | DHFR, DPYD, CYP2D6 | BACE1 3067/4885MRGPRX4 2081/4885FFAR4 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.